Does Sequential vs Concurrent Treatment Change Outcomes in HER2+ Breast Cancer?

Outcomes for patients with HER2-positive breast cancer did not differ when treated with sequential chemotherapy plus trastuzumab compared with a concurrent approach.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

Conclusions: Survival rates of patients with HER2+ breast cancer in our study are comparable to those seen in clinical trials. Our findings support chemotherapy de-escalation in patients with node-negative disease and validate the efficacy of FEC-DH in those with node-positive disease. PMID: 30659129 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Humphries MP, Hynes S, Bingham V, Cougot D, James J, Patel-Socha F, Parkes EE, Blayney JK, O'Rorke MA, Irwin GW, McArt DG, Kennedy RD, Mullan PB, McQuaid S, Salto-Tellez M, Buckley NE Abstract The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, there is a lack of consensus on how to deliver PD-L1 as a clinical biomarker. At the heart of this conundrum is the subjective scoring of PD-L1 IHC in most studies to date. Current standard scoring systems involve separation of epithelial and inflammatory cells and find clinical significance in different percentages of e...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
ConclusionsThe agreement of HER2 and Ki67 between CNB and paired surgical specimen in primary breast cancer is insufficient. Limited agreement of surrogate tumor subtypes indicates a significant clinical value of biomarker re-testing on surgical specimens.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsT-DM1 exhibited preclinical activity in HER2-overexpressing BTC. Further evaluation in clinical studies is warranted.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
DESTINY-Breast04 to evaluate [fam-] trastuzumab deruxtecan (DS-8201) versus investigator's choice in HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy No anti-HER2 therapies are currently approved for H... Biopharmaceuticals, Oncology Daiichi Sankyo, trastuzumab, breast cancer, HER2
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
The Opti-HER HEART trial examined whether liposomal formulations of chemotherapy agents may reduce cardiac toxicity in HER2+ breast cancer patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
AbstractPurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23  months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [hazard ratio (HR) 0.58;P 
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conclusion.One in six patients with early‐stage breast cancer received guideline‐discordant care, predominantly related to undertreatment, which was associated with higher costs and rates of health care utilization. Additional randomized trials are needed to test lower‐toxicity regimens and guide clinicians in treatment for older breast cancer patients.Implications for Practice.Previous studies lack details about types of deviations from chemotherapy guidelines that occur in older early‐stage breast cancer patients. Understanding the patterns of guideline discordance and its impact on patient outcomes will be parti...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer, Health Outcomes and Economics of Cancer Care, Geriatric Oncology Source Type: research
Abstract PURPOSE: To investigate the association of insulin like growth factor 1 receptor (IGF-1R) and estrogen receptor (ER) with pathological complete response (pCR) secondary to neoadjuvant chemotherapy in human epidermal growth factor receptor-2 (HER2)-negative breast cancer. MATERIALS AND METHODS: The immunohistochemical expressions of IGF-1R and ER were detected in puncture specimens from 273 patients who received neoadjuvant chemotherapy. Association of IGF-1R and ER expression with pCR to neoadjuvant chemotherapy was evaluated. RESULTS: In 273 cases of breast cancer, the high expression rate of I...
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
Authors: Seo Y, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY Abstract Purpose: PIK3CA mutation is considered to be a possible cause for resistance to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the association between PIK3CA mutations and the outcome of NAC in HER2-positive breast cancers. Methods: A total of 100 HER2-positive breast cancer patients who had undergone NAC and surgery between 2004 and 2016 were examined. Mutation status was sequentially assessed in pre-NAC, post-NAC, and recurrent specimens taken from these patients. ...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin